Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-04-24
2007-04-24
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100, C435S235100, C435S325000, C435S320100, C536S023720
Reexamination Certificate
active
09083793
ABSTRACT:
Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.
REFERENCES:
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/11093 (1997-03-01), None
patent: WO 97/20468 (1997-06-01), None
patent: 99/02657 (1999-01-01), None
Kato et al, Genes to Cells 1:569-579, Jun. 1996.
Conzelmann, “Genetic manipulation of non-segmented negative-strand RNA viruses,”J. Gen. Virol. 77:381-89 (1996).
Cook et al., “In Vivo antigenic Studies of Parainfluenza Viruses,”Amer. Jour. Hyg. 77:150, 1963.
Cook et al., “Antigenic Relationships Among the “Newer” Myxoviruses (Parainfluenza),”Amer. Jour. Hyg. 69:250, 1959.
Dimock and Collins, “Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3,”J. Virol. :2772-2778, 1993.
Durbin et al., “Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA,”Virology 235:323-332, 1997.
Durbin et al., “Minimum protein Requirements for Transcription and RNA Replication of a Minigenome of Human Parainfluenza Virus Type 3 and Evaluation of the Rule of Six,”Virology234:74-78 (1997).
Flexner et al., “Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression,”Nature33:259-262, 1987.
Frank et al. “Comparison of Different Tissue Cultures for Isolation and Quantitation of Influenza and Parainfluenza Viruses,”J. Clin. Microbiol. 10:32-6 (1979).
Fuerst et al., “Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase,”Proc. Natl. Acad. Sci. USA83:8122-8126, 1986.
Galinski et al., “Molecular cloning and Sequence Analysis of the Human parainfluenza 3 Virus Gene Encoding the L Protein,”Virology 165: 499-510, (1988).
Galinski et al., “RNA Editing in the Phosphoprotein Gene of the Human Parainfluenza Virus Type 3,”Virology 186: 543-50 (1992).
Garcin et al., “A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus,”EMBO J. 14(24) :6087-6094 (1995).
Grosfeld et al., “RNA Replication by Respiratory Syncytial Virus (RSV) Is Directed by the N, P, and L Proteins; Transcription Also Occurs under These Conditions but Requires RSV Superinfection for Efficient Synthesis of Full-Length mRNA,”J. Virol. 69: 5677-5686 (1995).
Hall et al., “Cold-passaged human parainfluenza type 3 viruses containtsand non-tsmutations leading to attenuation in rhesus monkeys,”Virus Res. 22(3) :173-184, 1992.
Karron et al., “A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children,”J. Infect. Dis. 171:1107-1114, 1995.
Kast et al., “Protection against lethal Sendai virus infection byin vivopriming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide,”Proc. Natl. Acad. Sci. USA 88:2283-2287, 1991.
Kunkel et al., “Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection,”Methods Enzymol. 154: 367-382, (1987).
Lawson et al., “Recombinant vesicular stomatitis viruses from DNA,”Proc. Natl. Acad. Sci. U.S.A.92:4477-81 (1995).
Murphy et al., “Failure of Attenuated Temperature-Sensitive Influenza A (H3N2) Virus to Induce Heterologous Interference in Humans to Parainfluenza Type 1 Virus,”Infect. Immun. 12:62-8, 1975.
Murphy et al., “Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses,”Virus Res. 11:1-15 (1988).
Murphy et al., “Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization,”Vaccine 8(5) :497-502, 1990.
Palese et al., “Negative-strand RNA viruses: Genetic engineering and application,”Proc. Natl. Acad. Sci. U.S.A.93:11354-58, (1996).
Pelet et al., “The P gene of bovine parainfluenza virus 3 expresses all three reading frames from a single mRNA editing site,”EMBO J. 10:443-448 (1991).
Radecke et al., “Rescue of measles viruses from cloned DNA,”EMBO J. 14:5773-5784 (1995).
Ray et al., “Human Parainfluenza virus Induces a Type-Specific Protective Immune Response,”J. Infect. Dis. 162:746, 1990.
Ray et al., “Temperature-Sensitive Phenotype of the Human Parainfluenza virus Type 3 Candidate Vaccine Strain (cp45) Correlates with a Defect in the L Gene,”J. Virol. 70:580-584 (1996).
Sakaguchi et al., “Expression of the HN, F, NP and M proteins of Sendai virus by recombinant vaccinia viruses and their contribution to protective immunity against Sendai virus infections in mice,”J. Gen. Virol. 74:479-484, 1993.
Schnell et al., “Infectious rabies viruses from cloned cDNA,”EMBO J.13:4195-203 (1994).
Skiadopoulos et al., “Three Amino Acid Substitutions in the L Protein of the Human Parainfluenza Virus Type 3 cp45 Live Attenuated Vaccine Candidate Contribute to Its Temperature-Sensitive and Attenuation Phenotypes,”J. Virol 72(3) :1762-1768, 1998.
Spriggs and Collins, “Sequence analysis of the P and C Protein Genes of Human parainfluenza Virus Type 3: Patterns of Amino Acid Sequence Homology among Paramyxovirus Proteins,”J. Gen. Virol. 672705-2719, (1986).
Stokes et al., “The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain,”Virus Res. 25:91-103 1992.
Stokes et al., “The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp 12 and cp 45) derived from the JS strain and human parainfluenza virus type 3 (PIV3),”Virus Res. 30(1) :43-52, 1993.
Tanabayashi, K. and Compans, R.W., “Functional Interaction of Paramyxovirus Glycoproteins: identification of a Domain in Sendai Virus HN Which Promotes Cell Fusion,”J. Virol. 70:6112-18 (1996).
Tao et al., “Recovery of a Fully Viable Chimeric Human Parainfluenza Virus (PIV) Type 3 in Which the Hemagglutinin-Neuraminidase and Fusion Glycoproteins Have Been Replaced by Those of PIV Type 1,”J. Virol. 72:2955-2961, 1998.
Thomson et al., “Recombinant Polyepitope Vaccines for the Delivery of Multiple CD8 Cytotoxic T Cell Epitopes,”J. Immunol. 157:822, 1996.
van Wyke Coelingh et al., “Antigenic and Structural Properties of the Hemagglutinin-Neuraminidase glycoprotein of Human Parainfluenza Virus Type 3: Sequence analysis of Variants Selected with Monoclonal antibodies Which Inhibit Infectivity, Hemagglutination, and Neuraminidase Activities,”J. Virol. 61:1473-1477, (1987).
van Wyke Coelingh et al., “Antigenic Variation in the Hemagglutinin-Neuraminidase Protein of Human Parainfluenza Type 3 Virus,”Virology 143(2) :569-582, 1985.
Whelan et al., “Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones,”Proc. Natl. Acad. Sci. USA92:8388-8392 (1995).
Baron et
Collins Peter L.
Durbin Anna P.
Murphy Brian R.
Skiadopoulos Mario H.
Tao Tao
Chen Stacy B.
The United States of America, represented by the Secretary, Depa
LandOfFree
Production of attenuated parainfluenza virus vaccines from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of attenuated parainfluenza virus vaccines from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of attenuated parainfluenza virus vaccines from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3779517